Literature DB >> 14597666

RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development.

Irit Adini1, Isaac Rabinovitz, Jing Fang Sun, George C Prendergast, Laura E Benjamin.   

Abstract

Blood vessel formation is a complex morphological process that is only beginning to be understood at the molecular level. In this study, we demonstrate a novel and critical role for the small GTPase, RhoB, in vascular development. RhoB null mice have retarded vascular development in the retina characterized by altered sprout morphology. Moreover, pharmaceutical means to deplete RhoB in neonatal rats is associated with apoptosis in the sprouting endothelial cells of newly forming vessels. Similarly, acute depletion of RhoB by antisense or dominant-negative strategies in primary endothelial cell culture models led to apoptosis and failures in tube formation. We identified a novel link between RhoB and the Akt survival signaling pathway to explain these changes. Confocal microscopy revealed that RhoB is highly localized to the nuclear margin with a small percentage found inside the nucleus. Similarly, total Akt is throughout the cell but has increased accumulation at the nuclear margin, and active phosphorylated Akt is found primarily inside the nucleoplasm, where it partially colocalizes with the RhoB therein. We show that this colocalization is functionally relevant, because when RhoB was depleted, Akt was excluded from the nucleus and total cellular Akt protein was decreased in a proteosome-dependent manner. Because the function of RhoB in vivo appears to only be rate limiting for endothelial cell sprouting, we propose that RhoB has a novel stage-specific function to regulate endothelial cell survival during vascular development. RhoB may offer a therapeutic target in diseases such as cancer, diabetic retinopathy, and macular degeneration, where the disruption of sprouting angiogenesis would be desirable.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14597666      PMCID: PMC280621          DOI: 10.1101/gad.1134603

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  48 in total

1.  Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors.

Authors:  Ping-Yao Zeng; Neena Rane; Wei Du; Janaki Chintapalli; George C Prendergast
Journal:  Oncogene       Date:  2003-02-27       Impact factor: 9.867

Review 2.  Farnesyltransferase inhibitors: promises and realities.

Authors:  Adrienne D Cox; Channing J Der
Journal:  Curr Opin Pharmacol       Date:  2002-08       Impact factor: 5.547

Review 3.  Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox.

Authors:  E Duh; L P Aiello
Journal:  Diabetes       Date:  1999-10       Impact factor: 9.461

4.  Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake.

Authors:  Aimee L Edinger; Craig B Thompson
Journal:  Mol Biol Cell       Date:  2002-07       Impact factor: 4.138

5.  Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity.

Authors:  P F Lebowitz; J P Davide; G C Prendergast
Journal:  Mol Cell Biol       Date:  1995-12       Impact factor: 4.272

6.  Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice.

Authors:  N E Kohl; C A Omer; M W Conner; N J Anthony; J P Davide; S J deSolms; E A Giuliani; R P Gomez; S L Graham; K Hamilton
Journal:  Nat Med       Date:  1995-08       Impact factor: 53.440

7.  Regulation of Ras-related RhoB protein expression during the cell cycle.

Authors:  G Zalcman; V Closson; G Linarès-Cruz; F Lerebours; N Honoré; A Tavitian; B Olofsson
Journal:  Oncogene       Date:  1995-05-18       Impact factor: 9.867

8.  Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity.

Authors:  T Alon; I Hemo; A Itin; J Pe'er; J Stone; E Keshet
Journal:  Nat Med       Date:  1995-10       Impact factor: 53.440

9.  Intracellular localization of the P21rho proteins.

Authors:  P Adamson; H F Paterson; A Hall
Journal:  J Cell Biol       Date:  1992-11       Impact factor: 10.539

10.  14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport.

Authors:  Anne Brunet; Fumihiko Kanai; Justine Stehn; Jian Xu; Dilara Sarbassova; John V Frangioni; Sorab N Dalal; James A DeCaprio; Michael E Greenberg; Michael B Yaffe
Journal:  J Cell Biol       Date:  2002-02-25       Impact factor: 10.539

View more
  73 in total

1.  The Renin-Angiotensin-Aldosterone System (RAAS) Is One of the Effectors by Which Vascular Endothelial Growth Factor (VEGF)/Anti-VEGF Controls the Endothelial Cell Barrier.

Authors:  Yueru Li; Zhonghao Yan; Komal Chaudhry; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2020-06-23       Impact factor: 4.307

2.  Regulating angiogenesis at the level of PtdIns-4,5-P2.

Authors:  Eunok Im; Andrius Kazlauskas
Journal:  EMBO J       Date:  2006-04-20       Impact factor: 11.598

3.  Mechanistic exploration of phthalimide neovascular factor 1 using network analysis tools.

Authors:  Kristen A Wieghaus; Erwin P Gianchandani; Milton L Brown; Jason A Papin; Edward A Botchwey
Journal:  Tissue Eng       Date:  2007-10

Review 4.  Nuclear and mitochondrial signalling Akts in cardiomyocytes.

Authors:  Shigeki Miyamoto; Marta Rubio; Mark A Sussman
Journal:  Cardiovasc Res       Date:  2009-03-11       Impact factor: 10.787

5.  Cardioprotective stimuli mediate phosphoinositide 3-kinase and phosphoinositide dependent kinase 1 nuclear accumulation in cardiomyocytes.

Authors:  Marta Rubio; Daniele Avitabile; Kimberlee Fischer; Gregory Emmanuel; Natalie Gude; Shigeki Miyamoto; Shikha Mishra; Eric M Schaefer; Joan Heller Brown; Mark A Sussman
Journal:  J Mol Cell Cardiol       Date:  2009-03-06       Impact factor: 5.000

6.  RhoJ is an endothelial cell-restricted Rho GTPase that mediates vascular morphogenesis and is regulated by the transcription factor ERG.

Authors:  Lei Yuan; Anastasia Sacharidou; Amber N Stratman; Alexandra Le Bras; Peter J Zwiers; Katherine Spokes; Manoj Bhasin; Shou-Ching Shih; Janice A Nagy; Grietje Molema; William C Aird; George E Davis; Peter Oettgen
Journal:  Blood       Date:  2011-05-31       Impact factor: 22.113

7.  RhoB deficiency in thymic medullary epithelium leads to early thymic atrophy.

Authors:  Arturo Bravo-Nuevo; Rebekah O'Donnell; Alexander Rosendahl; Jae Hoon Chung; Laura E Benjamin; Chikako Odaka
Journal:  Int Immunol       Date:  2011-08-23       Impact factor: 4.823

8.  RhoB loss prevents streptozotocin-induced diabetes and ameliorates diabetic complications in mice.

Authors:  Arturo Bravo-Nuevo; Hikaru Sugimoto; Seema Iyer; Zachary Fallon; Jason M Lucas; Shiva Kazerounian; George C Prendergast; Raghu Kalluri; Nathan I Shapiro; Laura E Benjamin
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

9.  Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure.

Authors:  Ichiro Shiojima; Kaori Sato; Yasuhiro Izumiya; Stephan Schiekofer; Masahiro Ito; Ronglih Liao; Wilson S Colucci; Kenneth Walsh
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

10.  RhoB regulates PDGFR-beta trafficking and signaling in vascular smooth muscle cells.

Authors:  Minzhou Huang; James B Duhadaway; George C Prendergast; Lisa D Laury-Kleintop
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-10-19       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.